Aster DM Healthcare Limited Overview
| Field | Detail | Source |
|---|---|---|
| Current legal name | Aster DM Quality Care Limited | Exchange filing, Jul 2026 |
| Former names | Aster DM Healthcare Private Limited (2008); Aster DM Healthcare Limited (after conversion to public company; until 3 Jul 2026) | InCred/IIFL company profile; Screener |
| Founding of group | 1987, when Dr. Azad Moopen opened a single clinic in Dubai | Bloomberg via Gulf News, Nov 2024 |
| Indian incorporation | 18 January 2008, as a private limited company | Company profile (InCred Money) |
| Incorporation jurisdiction | India (Companies Act). Merger scheme sanctioned by NCLT Hyderabad Bench | NCLT order coverage, Jan 2026 |
| Headquarters / corporate office | Bengaluru, Karnataka (press releases are datelined Bengaluru). | Q4 FY26 and Q1 FY27 press releases |
| Exchanges and tickers | NSE: ASTERDM; BSE: 540975 | NSE/BSE filings |
| ISIN | INE914M01019 | Exchange data (Bigul) |
| CUSIP | Not applicable (no US listing) | — |
| Fiscal year end | 31 March | Company filings |
| Statutory auditor | Deloitte Haskins & Sells (limited review of Q1 FY27 results) | Q1 FY27 board outcome, 5 Aug 2026 |
| Shares outstanding | 871,672,439 equity shares of INR 10 each after merger allotment (up from 518,121,029) | SAST disclosure, Jul 2026 |
| Employees (merged entity) | Over 45,000 professionals | Merger completion disclosure, 2 Jul 2026 |
| Employees (3-year trend) | Standalone India headcount trend is not publicly disclosed in the sources reviewed. Pre-separation group (incl. GCC) had 34,239 staff | Aster DM Foundation page (GCC-era) |
| Market capitalisation | About INR 61,793 crore at INR 708.90 per share on 1 Oct 2026 | IIFL / InCred Money |
| Credit ratings | ICRA AA (Stable) / A1+ (Jul 2026); CRISIL AA+ (Stable) / A1+ (Jul 2026) | ICRA and CRISIL rationales |
| Website (listed entity IR) | asterdmhealthcare.in (IR); hospital brand sites remain separate | Company IR pages |
Aster DM Quality Care is a hospital-led integrated healthcare platform in India. It was formed on 1 July 2026 by merging the founder-led Aster DM Healthcare with Blackstone-controlled Quality Care India. The combined network spans 39 hospitals across 28 cities and more than 10,890 beds under four brands: Aster, CARE Hospitals, KIMSHEALTH and Evercare [Src: Q1 FY27 press release, Aug 2026]. Its footprint is concentrated in South and Central India and Bangladesh, with deliberate exposure to Tier-2 and Tier-3 cities such as Nagpur, Vijayawada and Raipur. Those markets have weaker incumbents and faster growth in insurance and private-hospital demand. On FY26 pro-forma figures, the platform generated INR 9,273 crore of revenue and INR 2,013 crore of operating EBITDA (21.7% margin) [Src: FY26 results, Apr 2026]. That places it in the top three Indian hospital chains by scale. The investment case rests on four things: brownfield-heavy bed additions, merger synergies, clinical depth in quaternary specialties, and joint promoter-PE governance. The main risks are integration execution and a rich valuation.
What the Company Does
The company owns and operates multi-specialty and super-specialty hospitals. It also runs clinics, a diagnostics network (Aster Labs and patient experience centres) and digital health channels. Retail pharmacy is run in a franchise-like format: the Aster Pharmacy stores in India are operated by Alfaone Retail Pharmacies Private Limited under a brand licence from Aster [Src: company IR "About Aster DM" page].
Before the merger, Aster DM Healthcare described itself as one of the largest healthcare providers in India. It said it covered primary, secondary, tertiary and quaternary care through 19 hospitals with about 4,867–4,994 beds, 13 clinics, roughly 212–217 brand-licensed pharmacies and 232–243 labs and patient experience centres across five to six states [Src: company IR page, various 2024–25 versions]. By Q3 FY26, standalone Aster reported 20 hospitals [Src: Q3 FY26 press release, Feb 2026]. Labs and PECs reached 321 in Q1 FY27 [Src: AskFuzz aggregation of Q1 FY27 presentation].
Business Model and Revenue Model
The business is overwhelmingly a service model. Revenue comes from inpatient (IP) and outpatient (OP) hospital services, priced per episode or per day of stay and paid by cash/self-pay patients, private insurers and TPAs, government schemes and international patients. There is no meaningful product, subscription or licensing revenue at group level. The exceptions are:
-
Brand-licence economics from the Alfaone-operated pharmacies.
-
Diagnostics revenue from Aster Labs, which is fee-for-service.
Key operating drivers disclosed by the company are:
-
Occupancy: 61% for Aster standalone in FY26; 64% blended pro-forma in Q1 FY27.
-
Average revenue per occupied bed (ARPOB): INR 51,800 for Aster in FY26.
-
Average revenue per inpatient (ARPP IP): INR 144,064 for Aster in Q1 FY27, up 9% YoY.
-
Patient volumes: about 2.01 million pro-forma in Q1 FY27, up 13% YoY.
[Src: FY26 results coverage (ScanX); Q1 FY27 press release and transcript summaries.]
Value-Chain Position and Customers
The company sits at the provider end of the healthcare value chain. It buys pharmaceuticals, consumables and equipment from suppliers. It employs or contracts clinicians and bills payers. Customers fall into five groups:
-
Domestic self-pay patients
-
Privately insured patients, a growing share of the market
-
Beneficiaries of government and public-sector schemes
-
Corporate tie-ups
-
International "medical value travel" (MVT) patients
MVT is material in the Kerala cluster. In Q2 FY26, MVT revenue rose 67% quarter on quarter [Src: FilingReader summary of Q2 FY26 results].
Company Self-Description vs. Independent Characterisation
Company language (paraphrased). Management positions the merged entity as one of India's leading integrated healthcare providers. It cites four trusted brands, a focus on clinical excellence, digitally enabled care and a bias toward high-quality clinical outcomes. It emphasises expanding specialist access to underserved Tier-2 and Tier-3 cities [Src: merger completion releases, Jul 2026].
Independent characterisation. In practice the merged entity is a regional-cluster hospital operator with two strong cores:
-
Kerala. This is Aster's historic base: Aster Medcity Kochi, Aster MIMS Calicut, Kannur and Kasaragod, and now KIMSHEALTH Thiruvananthapuram.
-
Telangana / Andhra Pradesh / Central India. This is the CARE Hospitals footprint plus Aster Ramesh and Aster Prime.
The Bengaluru cluster (Aster CMI, Aster RV, Aster Whitefield) and Bangladesh (Evercare) are secondary pillars. Diagnostics and pharmacy are adjacencies, not profit engines. Aster Labs only reached a 12.8% operating EBITDA margin in FY26, up from 7.6% in FY25 [Src: AGM highlights, Oct 2026].
The platform's economic character is mid-ARPOB, volume-led and cluster-dense. It differs from the premium metro-ARPOB model of Max Healthcare (about INR 77,800 ARPOB in FY26) [Src: Upstox peer comparison, 2026].
Strategy
Stated Strategic Themes (paraphrased from 2026 disclosures)
-
Scale to top-three in India. The merger is positioned as creating one of the top three hospital chains in India by beds and revenue [Src: merger releases].
-
Tier-2 and Tier-3 access. Expand specialist care, advanced treatment and medical technology in cities such as Nagpur, Vijayawada and Raipur [Src: merger completion disclosure].
-
Brownfield-led capacity growth. Pipeline of about 4,170 beds to exceed 15,000 beds, with about 53% brownfield to raise capital efficiency [Src: AGM highlights, Oct 2026].
-
Clinical excellence and centres of excellence. Shared protocols, multidisciplinary consultations and integrated centres of excellence across the four brands [Src: AskFuzz merger summary].
-
Technology. Investment in robotics and radiation therapy (Gamma Knife, ZAP), digital health platforms and exploration of agentic AI [Src: AGM].
-
Synergies. Procurement, digital health and clinical collaboration [Src: merger completion]. One aggregator cites an expected 10–15% EBITDA uplift [Src: AskFuzz]. ICICI Direct references a figure of about INR 150–200 crore in its Aug 2026 update, though the context is only partially visible.
-
Capital discipline. Management confirmed no further dividends or bonus issues are planned for now, prioritising capital deployment [Src: AGM highlights].
Initiative Register (last 24 months)
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Nov 2024 | Merger with QCIL | All-stock; 977 Aster shares per 1,000 QCIL shares | Company; Mint |
| May–Jun 2025 | Organic expansion plan | About 2,100 Aster beds (of about 3,300 combined) for about INR 1,878–1,900 crore | Outlook Business; Towards Healthcare |
| Oct 2025 | Kasaragod launch | 263–264 beds, North Kerala | Q2 FY26 |
| Apr 2026 | Enlarged expansion plan | 4,080 beds for about INR 4,000 crore (2,368 by Aster) | Outlook Business, Apr 2026 |
| Jul 2026 | Merger completion and new organisation | Regional CEOs; CDO; Group CPO; Group Legal | Board outcome |
| Aug 2026 | FY30 capacity ambition | 4,179 beds to reach 15,077 | Q1 FY27 presentation |
| Sep 2026 | Capital allocation framework | INR 6,900 crore over FY27–FY29 | AGM addendum |
| Ongoing | Diagnostics profitability-first | Labs margin 7.6% to 12.8% | AGM |
| Ongoing | Pharmacy profitability over expansion | Management stance on labs and pharmacy | DigitalHealthNews |
Medium-Term Targets and Guidance
No formal numerical revenue or margin guidance was provided in statutory results [Src: Quartr Q2 FY26 summary]. Quantified intentions are:
-
Bed capacity above 15,000.
-
Capital deployment of INR 1,900 crore in FY27, INR 3,000 crore in FY28 and INR 2,000 crore in FY29.
-
Merger benefits expected from FY27 onward [Src: Outlook Business interview, 2025].
Products & Services
Hospital groups do not publish SKU-style catalogues or list prices. Pricing is episode-based and payer-negotiated, and is not publicly disclosed. The portfolio below is organised by brand, facility and service line. Facility bed counts and dates are given where verified. Facilities listed from general knowledge without a verified source are flagged "(verify)".
Brand: Aster (legacy Aster DM Healthcare India)
| Facility / offering | Location | Level of care / notes | Status / latest data | Source |
|---|---|---|---|---|
| Aster Medcity | Kochi, Kerala | Quaternary flagship; 100-bed expansion underway; margin about 30% | Operational since 2014 | Company releases |
| Aster MIMS Calicut | Kozhikode, Kerala | Tertiary/quaternary | Operational | Company releases |
| Aster MIMS Kannur | Kannur, Kerala | Tertiary; launched with 302 beds; 100-bed expansion planned | Operational since Q4 FY19 | Company profile |
| Aster MIMS Kasaragod | Kasaragod, Kerala | Multi-specialty, about 263–264 beds | Commenced 2 Oct 2025 | Q2 FY26 presentation |
| Aster MIMS Kottakkal | Malappuram, Kerala | Secondary/tertiary (verify) | Operational | General knowledge |
| Aster Capital Hospital | Thiruvananthapuram, Kerala | Greenfield tertiary, 454 beds | Under construction | Apr 2026 release |
| Aster CMI | Bengaluru (Hebbal) | Tertiary/quaternary; +350-bed expansion | Operational | Apr 2026 release |
| Aster RV | Bengaluru (JP Nagar) | Tertiary (verify) | Operational | General knowledge |
| Aster Whitefield | Bengaluru | Multi-specialty; +159-bed expansion (H2 FY26) | Operational | Q2 FY26 presentation |
| Aster Sarjapur Road hospital | Bengaluru | Greenfield, 430 beds, about INR 480 crore investment; SPV Aster DM-Super Specialty Hospital (Sarjapur) Pvt Ltd (INR 45.09 crore invested in Q1 FY27) | Under construction | DigitalHealthNews; Q1 FY27 standalone notes |
| Aster Yeshwanthpur | Bengaluru | Multi-specialty, 500 beds | Pipeline | Q2 FY26 presentation; Apr 2026 release |
| Aster Aadhar | Kolhapur, Maharashtra | Multi-specialty; held via Prerana Hospital Ltd; remaining 13% stake acquired | Operational | Business Standard topic page; ICRA |
| Aster Ramesh Hospitals | Vijayawada, Guntur and others, Andhra Pradesh | Multi-specialty; Aster Ramesh Ongole slated to commence in H2 FY26 | Operational | Q2 FY26 presentation |
| Aster Prime | Hyderabad, Telangana | Multi-specialty (verify) | Operational | General knowledge |
| Aster Women & Children | Hyderabad | 300-bed mother-and-child hospital; about INR 220 crore investment; target H1 FY27 | Under development | IIFL; Q2 FY26 presentation |
| Aster Clinics (13) | Kerala/Karnataka and others | Primary care | Operational | Company IR page |
| Aster Labs and PECs | Multi-state | Diagnostics; 321 labs and PECs (Q1 FY27) | Operational | Q1 FY27 data aggregation |
| Aster Pharmacy (India) | Multi-state | About 212–217 stores operated by Alfaone Retail Pharmacies under brand licence | Operational | Company IR page |
| Aster@Home | Bengaluru/Kerala | Home care services | Operational | DigitalHealthNews |
| Aster Health app | Pan-India | Appointments, e-pharmacy, digital records | Live | DigitalHealthNews |
Brand: CARE Hospitals (QCIL legacy)
CARE Hospitals was founded in 1997 in Hyderabad. It is QCIL's largest brand, with a footprint across Telangana, Andhra Pradesh, Odisha, Chhattisgarh, Maharashtra (Nagpur) and Madhya Pradesh (Indore) [Src: CB Insights for founding year; footprint per general knowledge — verify facility list]. Post-merger, management named Nagpur, Vijayawada and Raipur as Tier-2 expansion targets [Src: merger completion disclosure]. A facility-level bed register for CARE is not publicly disclosed in the reviewed sources.
Brand: KIMSHEALTH (QCIL legacy)
KIMSHEALTH is a tertiary/quaternary brand anchored in Thiruvananthapuram, Kerala. It strengthens the Kerala cluster alongside Aster Medcity and the MIMS hospitals. It is distinct from Krishna Institute of Medical Sciences (KIMS, a listed peer). The facility register is not publicly disclosed in the reviewed sources.
Brand: Evercare (QCIL legacy, Bangladesh)
Evercare operates hospitals in Bangladesh, at Dhaka and Chattogram per general knowledge (verify). QCIL describes its network as spanning India and Bangladesh [Src: Wealthy.in citing company]. A dedicated Bangladesh regional CEO was appointed on 1 July 2026 [Src: board outcome].
Flagship Clinical Technologies and Programs
| Technology / program | Description | Source |
|---|---|---|
| Gamma Knife | Stereotactic radiosurgery platform | 18th AGM disclosures |
| ZAP stereotactic radiosurgery | Self-shielded radiosurgery system for brain lesions | 18th AGM disclosures |
| Robotic surgical systems | Multi-specialty robotics across network | 18th AGM; merger completion release |
| Structural heart (TAVI, valve-in-valve) | First valve-in-valve with a self-expanding Evolut valve at Aster Whitefield | Q2 FY26 presentation |
| Agentic AI exploration | For patient engagement, diagnostics and precision medicine | 18th AGM disclosures |
| International patient (MVT) program | Kerala-centred; MVT revenue +67% QoQ in Q2 FY26 | FilingReader Q2 FY26 |
Financial Narrative
Basis of Preparation
Three bases are used below:
- Aggregator data (StockAnalysis, consolidated, INR million converted to crore). Provides a consistent five-year series.
Company-reported figures: Used for revenue, company-defined operating EBITDA and net profit where available.
Ratings-agency data (ICRA, CRISIL): Used for balance-sheet items.
FY22 includes the GCC business and is not comparable with FY23–FY26, which reflect continuing India operations after the GCC business was reclassified as discontinued. Blank cells mean the item is not publicly disclosed in the sources reviewed.
Income Statement
[Src: StockAnalysis income statement (FY22–FY26); company FY26 results (operating EBITDA, net profit INR 464 crore, normalised PAT INR 421 crore, +18%). FY25 net profit of INR 5,407.89 crore includes the GCC divestment gain (Towards Healthcare citing company). FY25 normalised PAT is derived from the stated 18% growth (421/1.18 ≈ 357) and should be treated as derived.]
EPS. Q2 FY26 basic EPS was INR 2.12 [Src: AlphaStreet]. Full-year FY26 EPS is not captured in the sources reviewed. A derived estimate of about INR 9.0 per share (INR 464 crore over about 51.8 crore pre-merger shares) is indicative only. FY25 EPS was inflated by the GCC gain. Diluted EPS is not publicly disclosed in the sources reviewed.
Margins
Revenue CAGR.
-
FY24–FY26: 12.0% (derived: 4,643 / 3,699 over two years).
-
FY23–FY26: 15.7% (derived).
-
Management's five-year claim: about 20% revenue CAGR and about 38% operating EBITDA CAGR [Src: Q2 FY26 earnings summary, Quartr]. PL Capital separately cites about 30% EBITDA CAGR over FY22–FY25 [Src: PL Capital Q2 FY26 note].
Commentary. The defining financial story of FY23–FY26 is margin expansion on a re-based, India-only asset base. Aggregator EBITDA margin rose about 570 bps, from 13.7% in FY23 to 19.4% in FY26. Company-defined operating EBITDA margin reached 20.4% in FY26. Three drivers explain this:
-
Ramp-up of maturing Kerala and Bengaluru hospitals. Matured-hospital margins are about 25–26.5%.
-
Case-mix and ARPOB improvement. ARPOB reached INR 51,800 in FY26.
-
Turnaround in diagnostics. Aster Labs moved from 7.6% to 12.8% operating EBITDA margin.
The inflection to watch is FY27. Two new hospitals (Kasaragod and Whitefield) and a Hyderabad women-and-children hospital will dilute margins initially; management already reports Kasaragod-excluded EBITDA. Merger-related costs are also a drag: INR 109.79 crore of exceptional professional fees and merger costs in Q1 FY27 standalone [Src: Q1 FY27 results]. Normalised PAT fell from INR 200 crore in Q2 FY26 to INR 125 crore in Q1 FY27 [Src: AskFuzz aggregation]. Some of these numbers come from an aggregator summary and should be cross-checked against filings.
Balance Sheet
[Src: FY25 debt (INR 2,017.8 crore), cash (INR 1,380.5 crore) and leverage ratios from ICRA rationale, Oct 2025. FY26 debt (INR 2,220 crore) and cash (INR 228 crore) from ICICI Direct company update, Aug 2026.]
Source conflict. ICICI Direct's FY26 cash figure of INR 228 crore implies FY26 net debt of about INR 1,992 crore. ICICI Direct also reports that Aster had a INR 511 crore net cash position at 30 June 2026, against QCIL debt of INR 1,673 crore, for combined net debt of INR 1,162 crore. The difference most likely reflects classification: lease liabilities included in "debt" and treasury investments or fixed deposits excluded from "cash". Both figures are reported here. The INR 1,162 crore combined net debt at 30 June 2026 is the more relevant post-merger number. CRISIL estimates pro-forma gearing at about 0.6x at 31 March 2026 [Src: CRISIL rationale, Jul 2026].
Total assets, equity, goodwill and intangibles, and working capital for the five-year span are not publicly disclosed in the sources reviewed. Goodwill will step up materially in FY27 under merger accounting.
Cash Flow
[Src: About INR 320 crore of expansion capex spent in FY25 per company statements via Towards Healthcare. INR 350–400 crore of capex incurred as of 30 Jun 2025 per ICRA. Special dividend outflow of about INR 5,894 crore in April 2024 (FY25) per directors' report.]
Operating cash flow, free cash flow and buybacks are not publicly disclosed in the sources reviewed. There have been no buybacks.
Forward capital deployment (company addendum to AGM notice). About INR 1,900 crore in FY27, INR 3,000 crore in FY28 and INR 2,000 crore in FY29, totalling about INR 6,900 crore [Src: AGM addendum, Sep 2026].
Ratios
Point-in-time ratios:
Current ratio, ROA, asset turnover and cash conversion cycle are not publicly disclosed in the sources reviewed. Hospital working capital is structurally light for cash patients, but insurance and scheme receivables extend it.
Interpretation of ROE vs ROCE. The gap between the low statutory ROE (about 7.75%) and management's pro-forma ROCE (about 23%) reflects two things. First, the equity base is inflated by retained GCC proceeds and merger equity. Second, management's ROCE excludes capital-work-in-progress and non-operating cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Revenue from operations (INR Cr) | 3,699 | 4,138 | 4,643 |
Revenue YoY growth (%) | 23.5 | 11.9 | 12.2 |
Operating EBITDA, company-defined (INR Cr) | — | 806 | 947 |
Operating EBITDA margin (%) | — | 19.5 | 20.4 |
Revenue by Segment and Segment Margins & Growth (%) — Combined pro-forma revenue
| Metric | FY24 | FY26 |
|---|---|---|
Combined pro-forma revenue (INR Cr) | 7,314 | 9,273 |
of which Aster (INR Cr) | 3,699 | 4,643 |
of which QCIL, derived (INR Cr) | 3,615 | 4,630 |
Combined pro-forma operating EBITDA (INR Cr) | 1,396 | 2,013 |
of which Aster operating EBITDA (INR Cr) | — | 947 |
of which QCIL operating EBITDA, derived (INR Cr) | — | 1,066 |
Combined operating EBITDA margin (%) | 19.1 | 21.7 |
Revenue by Segment
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Aster revenue (INR Cr) | 1,078 | 1,197 | 1,186 | 1,182 | 1,311 |
Aster operating EBITDA (INR Cr) | — | 263 | 237 | 244 | 279 |
QCIL revenue (INR Cr) | — | 1,193 | 1,181 | — | 1,287 |
QCIL operating EBITDA (INR Cr) | — | 287 | — | — | 299 |
Combined pro-forma revenue (INR Cr) | — | 2,390 | 2,366 | 2,361 | 2,597 |
Combined pro-forma operating EBITDA (INR Cr) | — | 550 | 503 | — | 576 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBusiness Units
| Unit | Latest disclosed KPI | Period | Source |
|---|---|---|---|
Kerala cluster | Record quarterly revenue INR 620 crore (+11–12% YoY); operating EBITDA +19% YoY; margin 26.8% (vs 25.0%) | Q2 FY26 | Q2 FY26 release |
Kerala cluster | Revenue +20% YoY; operating EBITDA +18% YoY | Q3 FY26 | Indian Pharma Post |
Aster Medcity (Kochi) | Revenue +24% YoY; operating EBITDA +33%; margin 30% | Q3 FY26 | Q3 FY26 release |
Aster Medcity (Kochi) | Revenue +16% YoY; operating EBITDA +26% | Q4 FY26 | Q4 FY26 release |
Aster MIMS Calicut | Revenue +14% YoY; EBITDA +20%; margin 26% | Q3 FY26 | Q3 FY26 release |
Aster MIMS Calicut | Revenue +21% YoY; EBITDA +41% | Q4 FY26 | Q4 FY26 release |
Aster Whitefield (Bengaluru) | Revenue +27% YoY | Q2 FY26 | Q2 FY26 presentation |
Aster Whitefield (Bengaluru) | Revenue +15% YoY; EBITDA +38% | Q4 FY26 | Q4 FY26 release |
Andhra & Telangana cluster | Operating EBITDA margin 13.2% (vs 7.9% in Q1 FY26) | Q2 FY26 | Q2 FY26 release |
Andhra & Telangana cluster | Revenue +13% YoY; EBITDA +7% | Q3 FY26 | Q3 FY26 release |
Core hospitals & clinics | Operating EBITDA margin 24.4% (vs 24.0%) | Q2 FY26 | Q2 FY26 release |
Matured hospitals | Operating EBITDA margin 26.5% (Q2 FY26); 25.1% (Q3 FY26) | Q2–Q3 FY26 | Releases |
Aster Labs | Revenue +15% YoY; margin 17.8% | Q2 FY26 | Investywise summary |
Aster Labs | Revenue +18% YoY | Q4 FY26 | Q4 FY26 release |
Aster Labs | Full-year operating EBITDA margin 12.8% (vs 7.6% in FY25) | FY26 | AGM highlights |
Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue, INR Cr (aggregator) | 10,253 | 2,994 | 3,699 | 4,139 | 4,643 |
Revenue YoY growth, % | 19.1 | -70.8 | 23.5 | 11.9 | 12.2 |
Gross profit, INR Cr | 3,667 | 1,559 | 1,976 | 2,292 | 2,719 |
Operating income (EBIT), INR Cr | 844 | 257 | 358 | 517 | 637 |
EBITDA, INR Cr (aggregator definition) | 1,211 | 410 | 533 | 706 | 901 |
Operating EBITDA, INR Cr (company definition) | — | — | — | 806 | 947 |
D&A, INR Cr | 367 | 153 | 175 | 189 | 264 |
Interest expense, INR Cr | 255 | 85 | 106 | 108 | 123 |
Net profit attributable, INR Cr (company) | — | — | — | 5,408 | 464 |
Normalised PAT, INR Cr (company) | — | — | — | 357 | 421 |
Dividend per share declared for the FY, INR | — | — | — | 118 | 3 |
Margin Analysis (%) — Gross margin, %
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Gross margin, % (derived) | 35.8 | 52.1 | 53.4 | 55.4 | 58.6 |
Operating (EBIT) margin, % (derived) | 8.2 | 8.6 | 9.7 | 12.5 | 13.7 |
EBITDA margin, % (aggregator) | 11.81 | 13.70 | 14.41 | 17.06 | 19.41 |
Operating EBITDA margin, % (company) | — | — | — | 19.5 | 20.4 |
Net margin on normalised PAT, % (derived) | — | — | — | 8.6 | 9.1 |
Financial Ratios (x)
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
Total debt, INR Cr | — | 2,018 | 2,220 |
Cash and equivalents, INR Cr | — | 1,381 | 228 |
Net debt, INR Cr (derived) | — | 637 | 1,992 |
Total debt to OPBDITA, x | 2.1 | 2.6 | — |
Net debt to OPBDITA, x | 2.1 | 0.8 | — |
Financial Analysis
| Metric | FY25 |
|---|---|
Capex, INR Cr (company-indicated) | 320 |
Dividends paid, INR Cr | 5,894 |
Financial Ratios (x) (FY22–FY26)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Interest coverage, EBIT to interest, x (derived) | 3.3 | 3.0 | 3.4 | 4.8 | 5.2 |
EBITDA to interest, x (derived) | 4.7 | 4.8 | 5.0 | 6.5 | 7.3 |
Financial Analysis — ROE
| Ratio | Value | As of | Source |
|---|---|---|---|
ROE (TTM) | 7.75% | Sep 2026 | Value Research |
ROCE (TTM) | 11.57% | Sep–Oct 2026 | Screener |
Pro-forma ROCE, merged entity | 22.9% | Q1 FY27 | Company (Investywise summary) |
Pro-forma ROCE (management) | Above 22% | Q2 FY26 | Q2 FY26 release |
ROCE change, Aster standalone | +330 bps YoY | FY26 | AGM highlights (ScanX) |
Pro-forma gearing | About 0.6x | 31 Mar 2026 | CRISIL |
Geographic Revenue
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Consolidated reported revenue, INR Cr | 10,253 | 2,994 | 3,699 | 4,139 | 4,643 |
Region / Cluster Details
| Region / cluster | Constituents | Latest disclosed revenue signal | Growth signal | Source |
|---|---|---|---|---|
Kerala | Aster Medcity, MIMS Calicut, Kannur, Kottakkal, Kasaragod; KIMSHEALTH | INR 620 crore (Q2 FY26, Aster only) | +20% YoY (Q3 FY26) | Q2 and Q3 FY26 releases |
Karnataka (Bengaluru) | Aster CMI, RV, Whitefield; Sarjapur and Yeshwanthpur in pipeline | Not disclosed in absolute terms | Whitefield +15% to +27% YoY | Q2 and Q4 FY26 |
Andhra Pradesh & Telangana | Aster Ramesh, Aster Prime; CARE Hyderabad cluster | — | Aster A&T +13% YoY (Q3 FY26) | Q3 FY26 |
Maharashtra | Aster Aadhar Kolhapur; CARE Nagpur (and others, verify) | — | — | — |
Central/East India | CARE Raipur, Bhubaneswar, Indore (verify) | — | QCIL emerging units +47% YoY | Q1 FY27 release |
Bangladesh | Evercare Dhaka, Chattogram (verify) | — | — | — |
“—” = not publicly disclosed.
Executive Leadership
Executive Leadership Team
| Name | Title | Effective | Background (as disclosed) | Source |
|---|---|---|---|---|
Dr. Azad Moopen | Executive Chairman; Executive Director (15 Apr 2026 to 28 May 2028) | Chairman since founding; ED term from Apr 2026 | Founder (1987). Previously Founder Chairman & MD | CB Insights; BW Healthcare |
Varun Khanna | Managing Director & Group CEO (five-year term) | 1 Jul 2026 | Formerly Group MD of QCIL (CARE, KIMSHEALTH, Evercare); about three decades of cross-sector experience | DigitalHealthNews; exchange filing |
Alisha Moopen | Board member (Moopen family nominee). Previously Deputy MD, Aster DM Healthcare India. Also MD & CEO of the separate Aster GCC business | — | Second-generation promoter | DigitalHealthNews; The National, Oct 2026 |
Sunil Kumar M R | Group CFO & Head of Investor Relations | 19 Jul 2026 | Previously CFO, Aster | FilingReader |
Pawan Kumar | Chief Executive, India II | 1 Jul 2026 | — | FilingReader |
Vinod Raman | Chief Digital Officer | 1 Jul 2026 | — | FilingReader |
Regional CEOs, India I and India III; CEO Bangladesh | Regional chief executives | 1 Jul 2026 | Names not captured in reviewed sources | Board outcome |
Group Chief People Officer; Group Legal Officer | New roles | 1 Jul 2026 | Names not captured | Board outcome |
Hemish Purushottam | Company Secretary & Compliance Officer (signatory on 2026 filings) | — | — | NSE filing, Mar 2026 |
Dr. Nitish Shetty | CEO, Aster DM Healthcare India (pre-merger) | — | Post-merger role not confirmed in reviewed sources | Company releases 2024–25 |
Hitesh Dhaddha | Chief Investor Relations and M&A Officer | Exited 18 Jul 2026 (personal reasons) | — | AskFuzz; FilingReader |
Board of Directors
| Name | Category | Change | Source |
|---|---|---|---|
Dr. Azad Moopen | Executive Chairman | Continuing | Company |
Varun Khanna | MD & Group CEO (additional director) | Appointed 1 Jul 2026 | Filing |
Alisha Moopen | Promoter director | Continuing | Choice India board page |
Neeraj Jain | Independent Director | Appointed 1 Jul 2026 | FilingReader |
Kewal Handa | Independent Director | Appointed 1 Jul 2026 | FilingReader |
V K Mathews | Independent Director | Appointed 1 Jul 2026 | FilingReader |
Ayshwarya Vikram | Non-Executive Director (Blackstone-side, inferred) | Appointed 1 Jul 2026 | FilingReader |
Ganesh Mani | Non-Executive Director (Blackstone-side, inferred) | Appointed 1 Jul 2026 | FilingReader |
Neela Bhattacherjee | Independent Director | Appointed 28 Sep 2026 | Screener announcements |
Purana Housdurgam Vijayadeepti | Independent Director | Retired 28 Sep 2026 | Screener announcements |
M Madhavan Nambiar | Independent Director | Resigned 1 Jul 2026 | FilingReader |
C J George | Independent Director | Resigned 1 Jul 2026 | FilingReader |
Zeba Azad Moopen | Non-Executive (promoter family) | Resigned 1 Jul 2026 | FilingReader |
A further non-executive director (surname "Haji" per filing fragment) | Non-Executive | Resigned 1 Jul 2026 | NSE filing fragment |
Major Shareholders
| Holder / category | Stake (%) | As of | Source |
|---|---|---|---|
Promoter and promoter group (total, foreign) | 53.71 | Jul 2026 | IIFL shareholding |
of which BCP Asia II Topco IV Pte. Ltd. (Blackstone), with persons acting in concert | 29.71 | Jul 2026 | SAST disclosure |
of which Aster promoters (Moopen family), merger-agreed level | About 24.0 | Jul 2026 | CRISIL rationale |
Centella Mauritius Holdings (TPG) | 9.90 | Jul–Sep 2026 | Centella correction disclosure (ScanX) |
Institutions (aggregate, non-promoter) | 26.79 | Jul 2026 | IIFL |
Promoter holding before merger | 40.39 | Mar–Jun 2026 | IIFL; Choice India |
FII / DII before merger | 10.53 / 0.41 | Pre-merger 2026 | Choice India |
Retail before merger | 21.42 | Pre-merger 2026 | Choice India |
Competitive Landscape
Key Competitors
| Competitor | Overlap with Aster DM Quality Care | Positioning |
|---|---|---|
Apollo Hospitals Enterprise | Pan-India, incl. Hyderabad, Bengaluru, Chennai | Largest chain: 76 hospitals, 10,970 licensed beds; FY26 revenue INR 25,228 crore [Src: Upstox] |
Manipal Health Enterprises | Bengaluru (home market) and pan-India | FY26 revenue INR 10,335 crore (+25.4%) [Src: Upstox] |
Max Healthcare Institute | Limited direct overlap (North/West India); ARPOB benchmark | 17 hospitals, 6,131 beds; ARPOB about INR 77,800 [Src: Upstox] |
Fortis Healthcare | Bengaluru and others | TTM revenue INR 9,506 crore [Src: Value Research] |
Narayana Health (Narayana Hrudayalaya) | Bengaluru; cardiac and affordable tertiary | TTM revenue INR 9,072 crore [Src: Value Research] |
Krishna Institute of Medical Sciences (KIMS, listed) | Direct in Telangana and Andhra Pradesh vs CARE and Aster Ramesh/Prime | Q2 FY26 revenue +23.6% YoY [Src: EY newsletter] |
Global Health (Medanta) | Expanding into Central/East India (Indore, Lucknow, Patna) | Market cap about INR 39,800 crore [Src: Screener] |
Rainbow Children's Medicare | Hyderabad and Bengaluru paediatrics/women's care vs the planned Aster W&C Hyderabad | Market cap about INR 14,700 crore [Src: Screener] |
Yashoda Hospitals (unlisted) | Hyderabad | — |
Kerala peers (VPS Lakeshore, Rajagiri, Amrita, Baby Memorial, Meitra) | Kerala cluster | — |
Dr. Agarwal's Health Care, Park Medi World, Yatharth | Adjacent listed comparables | Smaller scale |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Aster DM Quality Care | Apollo Hospitals | Fortis Healthcare | Max Healthcare | Narayana Health |
|---|---|---|---|---|---|
Revenue TTM (INR Cr) | 4,876 | 26,430 | 9,506 | 8,712 | 9,072 |
Net profit TTM (INR Cr) | 402.49 | 2,127.3 | 1,052.4 | 1,457.4 | 823.59 |
Net margin (%) | 8.04 | 7.99 | 11.01 | 16.41 | 9.02 |
ROE (%) | 7.75 | 22.66 | 11.05 | 14.39 | 20.09 |
P/E (x) | 214.94 | 59.66 | 65.56 | 65.80 | 46.55 |
Market cap (INR Cr) | 68,496 | 124,661 | 68,701 | 95,868 | 37,993 |
R&D intensity (%) | 0 | 0 | 0 | 0 | 0 |



